Therapeutic Index
| Category | Glossary |
|---|---|
| Also known as | Therapeutic Window, Safety Margin, TI |
| Last updated | 2026-04-13 |
| Reading time | 4 min read |
| Tags | pharmacologysafetydosingglossary |
Overview
The therapeutic index (TI) is a ratio that quantifies the relative safety of a drug by comparing the dose at which toxic effects occur to the dose at which the desired therapeutic effect is achieved. A larger therapeutic index indicates a wider margin between efficacy and toxicity, and therefore a greater safety margin.
The classical definition expresses the therapeutic index as:
TI = TD50 / ED50
Where TD50 is the dose that produces toxic effects in 50% of the population and ED50 is the dose that produces the desired effect in 50% of the population. In practice, more conservative measures (e.g., TD1/ED99) may be used for drugs with serious potential toxicity.
Detailed Explanation
Interpreting the Therapeutic Index
- High TI (e.g., >10) — Wide safety margin. The toxic dose is many times higher than the effective dose. There is substantial room for dosing variation without encountering toxicity. Examples include many common analgesics and antibiotics.
- Low TI (e.g., <2) — Narrow safety margin. The toxic dose is close to the effective dose. These drugs require careful dose titration, therapeutic drug monitoring, and close clinical oversight. Examples include warfarin, lithium, and digoxin.
- TI = 1 — The effective dose and toxic dose are identical, meaning the drug cannot produce a therapeutic effect without toxicity. Such drugs are not clinically useful.
Therapeutic Window
The therapeutic window is a related concept that defines the range of drug concentrations (or doses) between the minimum effective concentration and the minimum toxic concentration. While the therapeutic index is a single ratio, the therapeutic window describes a range and is often more clinically useful:
- Below the window — Subtherapeutic; insufficient drug to produce the desired effect.
- Within the window — Therapeutic; the drug produces the desired effect without significant toxicity.
- Above the window — Toxic; adverse effects outweigh benefits.
Factors Influencing the Therapeutic Index
- Pharmacokinetic variability — Differences in absorption, distribution, metabolism, and excretion between individuals can shift effective and toxic doses, effectively narrowing or widening the therapeutic index for specific populations.
- Drug interactions — Co-administered substances that alter metabolism can change drug levels, shifting them out of the therapeutic window.
- Patient factors — Age, organ function, genetic polymorphisms, and body composition all influence individual pharmacokinetics and pharmacodynamics.
- Route of administration — The same drug may have a different effective therapeutic index depending on whether it is administered orally, subcutaneously, or intravenously.
Limitations
The therapeutic index is a population-level statistic derived from dose-response curves and does not predict individual responses. A drug with a high population-level TI may still produce toxicity in a susceptible individual, and a drug with a low TI may be safe in a carefully monitored patient.
Relevance to Peptide Research
The therapeutic index concept is relevant to peptide research in several ways:
- Safety assessment — Many research peptides lack formal toxicology data, making their therapeutic index unknown. Without established TD50 values, the safety margin cannot be quantified.
- Dose selection — When preclinical data are available, the therapeutic index informs dose selection for research protocols. A peptide with a wide TI in animal studies provides more confidence in dose selection than one with a narrow TI.
- Peptide advantages — Peptides as a class often exhibit relatively favorable safety profiles due to their specificity for biological targets and their rapid degradation to naturally occurring amino acids. However, this generalization does not substitute for compound-specific data.
- IND requirements — Establishing the therapeutic index through preclinical toxicology studies is a key component of the IND submission process.
Examples
- A peptide shows efficacy in a rodent model at 10 mcg/kg and no observable adverse effects at 500 mcg/kg, suggesting a favorable therapeutic index of at least 50:1 in that species.
- Lithium has a therapeutic index of approximately 2–3, requiring regular blood level monitoring to maintain concentrations within the narrow therapeutic window.
- A researcher reviewing preclinical data for a research peptide notes that the maximum tolerated dose is only twice the minimum effective dose, indicating a narrow therapeutic index that warrants caution.
Related Terms
- Dose-Response Curve — The data from which therapeutic index is derived
- EC50 — The concentration producing 50% of the maximum effect, related to the ED50 used in TI calculations
- Half-Life — Influences drug accumulation and the risk of exceeding the therapeutic window
- Off-Label Use — Safety margin considerations are heightened when drugs are used outside their approved parameters
- IND — Regulatory pathway that requires therapeutic index characterization
Related entries
- Dose-Response Curve— The graphical representation of the relationship between drug dose and biological effect, central to understanding peptide potency, efficacy, and safe dosing ranges.
- EC50— The concentration of a substance that produces 50% of its maximal possible effect — a standard pharmacological measure of potency used to characterize agonist dose-response relationships.
- Half-Life— The concept of biological half-life as it applies to peptide pharmacokinetics — how long a compound remains active in the body and its implications for dosing frequency.
- IND (Investigational New Drug)— A regulatory submission to the FDA that must be approved before an unapproved drug or biological product can be administered to humans in a clinical trial, establishing safety and manufacturing standards.
- Off-Label Use— The use of an approved pharmaceutical product for an indication, dosage, route of administration, or patient population that has not received formal regulatory approval, a common but legally complex practice in medicine.